# Effect of IFN-γ on Innate Immune Cells

> **NCT02609932** · PHASE1 · COMPLETED · sponsor: **University of Colorado, Denver** · enrollment: 20 (actual)

## Conditions studied

- Chronic Granulomatous Disease

## Interventions

- **DRUG:** Administration of drug (Interferon-gamma 1-b) subcutaneously

## Key facts

- **NCT ID:** NCT02609932
- **Lead sponsor:** University of Colorado, Denver
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-07
- **Primary completion:** 2018-08
- **Final completion:** 2019-02
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2019-02-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02609932

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02609932, "Effect of IFN-γ on Innate Immune Cells". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT02609932. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*